Monoclonal Antibody Or Fragment Thereof (i.e., Produced By Any Cloning Technology) Patents (Class 424/141.1)
Human (Class 424/142.1)
Binds receptor (Class 424/143.1)
Binds hormone or other secreted growth regulatory factor, differentiation factor, or intercellular mediator (e.g., cytokine, etc.); or binds serum protein, plasma protein (e.g., tpa, etc.), or fibrin (Class 424/145.1)
Binds enzyme (Class 424/146.1)
Binds virus or component thereof (Class 424/147.1)
Binds bacterium or component thereof or substance produced by said bacterium (Class 424/150.1)
Binds parasitic organism (i.e., parasitic protozoan, multicellular ectoparasite (e.g., flea, tick, mite, etc.), or multicellular endoparasite (e.g., parasitic worm, etc.)) or component thereof or substance produced by said parasitic organism (Class 424/151.1)
Binds eukaryotic cell or component thereof or substance produced by said eukaryotic cell (Class 424/152.1)
  • Antibodies against and methods for producing vaccines for respiratory syncytial virus
    Patent number: 8852608
    Abstract: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.
    Type: Grant
    Filed: December 23, 2009
    Date of Patent: October 7, 2014
    Assignee: MedImmune, LLC
    Inventors: Josephine McAuliffe, Frances Palmer-Hill, Qing Zhu, Joann Suzich
  • Antibodies against IL-17BR
    Patent number: 8852589
    Abstract: The invention provides the antibody D9.2 and antibody molecules based on D9.2 which bind interleukin-17 receptor B. These may be useful in therapy, e.g. the treatment of asthma, ulcerative colitis or Crohn's disease.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: October 7, 2014
    Assignee: Medical Research Council
    Inventors: Andrew Neil James McKenzie, Daniel Neill
  • Anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
    Patent number: 8852597
    Abstract: Improved anti-CD154 antibodies are provided herein which have ablated FcR binding. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation and allergic disorders is disclosed herein.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: October 7, 2014
    Assignee: The Trustees of Dartmouth College
    Inventor: Randolph J. Noelle
  • CLEAVABLE DRUG CONJUGATES, COMPOSITIONS THEREOF AND METHODS OF USE
    Publication number: 20140294851
    Abstract: Base-labile crosslinkers, base-labile conjugates comprising such crosslinkers, methods of their synthesis and use are disclosed.
    Type: Application
    Filed: April 1, 2013
    Publication date: October 2, 2014
    Inventor: MARK QUANG NGUYEN
  • Stabilizing alkylglycoside compositions and methods thereof
    Patent number: 8846044
    Abstract: The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example parathyroid hormone (PTH) or PTH analogs, amylin, a monoclonal antibody, insulin, Peptide T or analog thereof, gastrin, gastrin releasing peptides, gastrin releasing peptide-like (GRP) proteins, epidermal growth factor or analog thereof.
    Type: Grant
    Filed: July 9, 2012
    Date of Patent: September 30, 2014
    Assignee: Aegis Therapeutics, LLC
    Inventor: Edward T. Maggio
  • Anti-LRP6 antibodies
    Patent number: 8846041
    Abstract: The invention provides anti-LRP6 antibodies and methods of using the same. A particular aspect of the invention provides for bispecific anti-LRP6 antibodies that inhibit signaling by multiple Wnt isoforms.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: September 30, 2014
    Assignee: Genentech, Inc.
    Inventors: Eric Bourhis, Tim Cao, Rick Carano, Andrea Cochran, Mike Costa, Venita DeAlmeida, James Ernst, Yan Gong, Rami Hannoush, Paul Polakis, Bonnee Rubinfeld, Mark Solloway, Yan Wu
  • Antibodies that bind to mammalian NGAL and uses thereof
    Patent number: 8846036
    Abstract: The present invention relates to antibodies specific for glycosylated mammalian NGAL, and to methods of making and using such antibodies.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: September 30, 2014
    Assignee: Abbott Laboratories
    Inventors: Larry G. Birkenmeyer, Suresh M. Desai, David J. Hawksworth, Edward T. Olejniczak, Qiaoqiao Ruan, Robert W. Siegel, Sergey Y. Tetin, Bryan C. Tieman, Bailin Tu, Robert N. Ziemann, Frank C. Grenier, Ryan F. Workman, Lowell Tyner
  • Anti-C5a receptor antibodies
    Patent number: 8846045
    Abstract: The present invention concerns human antibodies recognizing the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.
    Type: Grant
    Filed: June 18, 2013
    Date of Patent: September 30, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Kristian Kjaergaard, Soeren Lund
  • Antibody-containing solution pharmaceuticals
    Patent number: 8840884
    Abstract: Antibody-containing solution formulations including a sugar as a stabilizer. Said solution formulations can further include a surfactant as a stabilizer.
    Type: Grant
    Filed: February 14, 2003
    Date of Patent: September 23, 2014
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Masaya Kakuta, Jun Kikuchi, Hidefumi Mizushima, Yoshimi Imaeda
  • Method of treating cancer with DLL4 antagonist and chemotherapeutic agent
    Patent number: 8840886
    Abstract: The invention provides methods for treating various types of cancer/tumor by administering the combination of Dll4 antagonists, in particular, Dll4 antibodies and fragments thereof that specifically bind human Dll4, and chemotherapeutic agents. Such combination therapies exhibit synergistic effects compared to the treatment with either agent alone. Thus, the methods of the invention are particularly beneficial for cancer patients who have low tolerance to the side effects caused by high dosages required for the treatment by either agent alone, by being able to reduce effective dosages. Pharmaceutical compositions and kits containing Dll4 antagonists and chemotherapeutic agents are also provided.
    Type: Grant
    Filed: July 23, 2013
    Date of Patent: September 23, 2014
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Irene Noguera-Troise, Gavin Thurston, Alain Thibault
  • Humanized AXL antibodies
    Patent number: 8841424
    Abstract: The present invention refers to monoclonal humanized antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.
    Type: Grant
    Filed: May 11, 2010
    Date of Patent: September 23, 2014
    Assignee: U3 Pharma GmbH
    Inventors: Peter Wirtz, Jens Ruhe, Takeshi Takizawa, Tomoko Takayama
  • Immunoglobulin molecules with improved characteristics
    Patent number: 8834871
    Abstract: The present invention provides for IgG1 molecules with improved characteristics. In particular, substitution mutations are provided that, in combination, facilitate improved placental transfer, improved serum half-life and improved FcRn binding. Substitution mutations are also provided, that in combination, can be used to block FcRn function and thereby increase the clearance rates of other (endogenous or exogenous) IgGs, block placental transport of IgGs and have increased affinity/reduced pH dependence for FcRn binding.
    Type: Grant
    Filed: March 27, 2012
    Date of Patent: September 16, 2014
    Assignee: The Board of the University of Texas System
    Inventor: E. Sally Ward Ober
  • Methods of treating fibroproliferative disorders of the kidney or reducing kidney fibrosis
    Patent number: 8834879
    Abstract: Materials and methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Exemplary zvegf4 antagonists include anti-zvegf4 antibodies, inhibitory polynucleotides, inhibitors of zvegf4 activation, and mitogenically inactive, receptor-binding variants of zvegf4. The materials and methods are useful in the treatment of, inter alia, fibroproliferative disorders of the kidney, liver, and bone.
    Type: Grant
    Filed: April 3, 2013
    Date of Patent: September 16, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Charles E. Hart, Stavros Topouzis, Debra G. Gilbertson
  • Antibodies directed to angiopoietin-2 and uses thereof
    Patent number: 8834880
    Abstract: Antibodies directed to the antigen Ang-2 and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen Ang-2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: September 16, 2014
    Assignee: MedImmune Limited
    Inventors: Larry L. Green, Qing Zhou, Bruce A. Keyt, Xiao-Dong Yang, Stephen Charles Emery, David Charles Blakey
  • COMPOSITE BIOMARKERS FOR NON-INVASIVE SCREENING, DIAGNOSIS AND PROGNOSIS OF COLORECTAL CANCER
    Publication number: 20140255418
    Abstract: The present invention concerns particular biomarkers for diagnosing and/or prognosticating colorectal cancer, in particular in a non-invasive manner. The methods and compositions concern analysis of methylation patterns of one or more genes from a set of 29 genes identified as described herein. In certain embodiments, the gene set includes at least P15.INK4b, SST, GAS7, CNRIP1, and PIK3CG.
    Type: Application
    Filed: October 16, 2012
    Publication date: September 11, 2014
    Inventors: Hicham Mansour, Roberto Incitti, Vladimir Bajic
  • Anti-PSGL-1 antibodies and methods of inducing cell death of an activated T cell
    Patent number: 8828397
    Abstract: Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: September 9, 2014
    Assignee: AbGenomics Cooperatief U.A.
    Inventors: Rong-Hwa Lin, Chung Nan Chang, Pei-Jiun Chen, Chiu-Chen Huang
  • Antibodies that bind tyrosyl-tRNA synthetases
    Patent number: 8828395
    Abstract: Hematopoietic-modulating compositions are provided comprising aminoacyl-tRNA synthetase polypeptides, including active fragments and/or variants thereof, as well as compositions comprising related agents such as antibodies and other binding agents. Also provided are methods of using such compositions in the treatment of conditions that benefit from the modulation of hematopoiesis.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: September 9, 2014
    Assignee: aTyr Pharma, Inc.
    Inventors: Jeffry Dean Watkins, Alain P. Vasserot, Rajesh Belani, Leslie Ann Greene, Ryan Andrew Adams
  • Silent Fc variants of anti-CD40 antibodies
    Patent number: 8828396
    Abstract: The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: September 9, 2014
    Assignee: Novartis AG
    Inventors: Christoph Heusser, James Rush, Karen Vincent
  • Cytomegalovirus surface protein complex for use in vaccines and as a drug target
    Patent number: 8828399
    Abstract: Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: September 9, 2014
    Assignee: The Trustees of Princeton University
    Inventors: Thomas Shenk, Dai Wang
  • Methods for treating IgE-mediated disorder
    Patent number: 8828394
    Abstract: This invention relates to methods of treating IgE mediated disorders such as allergy and asthma based on activating surface-bound IgD molecules on basophils. The invention also relates to methods of making IgD, as well as methods of screening for antimicrobial agents from IgD-activated basophils.
    Type: Grant
    Filed: April 1, 2010
    Date of Patent: September 9, 2014
    Assignee: Cornell University
    Inventors: Andrea Cerutti, Kang Chen
  • Uses of NOGO-A inhibitors and related methods
    Patent number: 8828390
    Abstract: The present invention is directed to Nogo-A antagonists useful for the control of blood glucose or blood insulin levels in a subject and related use and formulation thereof. In particular, the invention is directed to Nogo-A antagonists useful for the prevention, repression or treatment insulin secretion deficiency and related methods and pharmaceutical formulations. In particular, the invention relates to Nogo-A antagonists useful in the treatment of diabetes mellitus.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: September 9, 2014
    Assignees: Universitat Zurich, Universite de Geneve
    Inventors: Pedro L. Herrera, Martin E. Schwab, Claire Bonal, Patrice Lalive D'epinay, Caroline Pot Kreis
  • Heparin-binding epidermal growth factor-like growth factor binding proteins
    Patent number: 8828382
    Abstract: Provided herein are antigen binding proteins, e.g., human and/or monoclonal antibodies that have affinity for heparin-binding epidermal growth factor-like growth factor (HB-EGF) and neutralize the biological functions of this growth factor.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: September 9, 2014
    Assignees: U3 Pharma GmbH, Amgen Inc.
    Inventors: Mike Rothe, Norbert Prenzel, Eric Borges, Thore Hettmann, Esther Zwick-Wallasch, Orit Foord
  • STABLE LYOPHILIZED PHARMACEUTICAL PREPARATIONS OF MONOCLONAL OR POLYCLONAL ANTIBODIES
    Publication number: 20140248274
    Abstract: The invention concerns lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies which contain a sugar or an amino sugar, an amino acid and a surfactant as stabilizers. In addition the invention concerns a process for the production of this stable lyophilisate as well as the use of a sugar or amino sugar, an amino acid and a surfactant as stabilizers for therapeutic or diagnostic agents containing antibodies.
    Type: Application
    Filed: May 12, 2014
    Publication date: September 4, 2014
    Applicant: ROCHE DIAGNOSTICS GMBH
    Inventors: Georg KALLMEYER, Gerhard WINTER, Christian KLESSEN, Heinrich WOOG
  • Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
    Patent number: 8822645
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Grant
    Filed: July 8, 2009
    Date of Patent: September 2, 2014
    Assignee: AbbVie Inc.
    Inventors: Tariq Ghayur, Jijie Gu, Peter C. Isakson
  • Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds and methods of use thereof
    Patent number: 8821871
    Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: September 2, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Joanne Van Ryn, Keith Canada, Robert Copenhaver, Norbert Hauel, Tobias Litzenburger, Christopher Ronald Sarko, Sanjaya Singh, Alisa K. Waterman
  • Identification and characterization of a specific CCK-C receptor antibody for human pancreatic cancer and its use for early detection and staging of pancreatic cancer
    Patent number: 8821872
    Abstract: Human pancreatic cancer cells possess a distinct plasma membrane CCK receptor variant that can be differentiated from the classic CCK-B receptor with selective monoclonal antibodies. Use of this receptor may be helpful in early detection or treatment of patients with pancreatic cancer.
    Type: Grant
    Filed: May 3, 2010
    Date of Patent: September 2, 2014
    Inventors: Jill P. Smith, Gail L. Matters, Neil D. Christensen, John F. Harms
  • KLK-13 antibody inhibitor for treating dry eye
    Patent number: 8821874
    Abstract: Disclosed herein is a method of treating dry eye with a KLK-13 antibody.
    Type: Grant
    Filed: July 22, 2013
    Date of Patent: September 2, 2014
    Assignee: Allergan, Inc.
    Inventors: Michael E. Stern, Christopher S. Schaumburg, Karyn F. Siemasko, Jianping Gao
  • Treatment of diffuse large-cell lymphoma with anti-CD20 antibody
    Patent number: 8821873
    Abstract: The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: September 2, 2014
    Assignee: Biogen Idec Inc.
    Inventors: Christine A. White, Antonio J. Grillo-Lopez
  • Methods and Compositions for Enhancing the Therapeutic Effect of Anti-Tumor T Cells
    Publication number: 20140241983
    Abstract: Compositions, e.g., therapeutic agents, and methods are provided for modulating gene and protein expression of Forkhead Box protein 1 (Foxp1). The therapeutic agents include short nucleic acid molecules that modulate gene and protein expression of Forkhead Box protein 1 (Foxp1) expression, viral vectors containing such molecules, T cells transduced with these viruses for adoptive therapies, and any small molecules that bind to and inactivate Foxp1. These compounds and methods have applications in cancer therapy either alone or in combination with other therapies that stimulate the endogenous immune system in the environment of the cancer, e.g., tumor.
    Type: Application
    Filed: October 24, 2012
    Publication date: August 28, 2014
    Applicant: The Wistar Institute of Anatomy and Biology
    Inventors: Hui Hu, Jose R. Conejo-Garcia, Tom-Li Stephen
  • Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
    Patent number: 8815240
    Abstract: The present invention relates to methods of diagnosing, and methods of treating, hepatocellular carcinoma in a subject. The invention also relates to antagonists of PLVAP proteins, such as antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising antagonists of PLVAP proteins. The invention further relates to humanized antibodies that specifically bind PLVAP protein.
    Type: Grant
    Filed: March 18, 2009
    Date of Patent: August 26, 2014
    Assignee: China Synthetic Rubber Corporation
    Inventors: Kuo-Jang Kao, Andrew T. Huang
  • Pharmaceutical composition with antibody that binds to heat shock protein 27(HSP270) and method for promoting wound healing
    Patent number: 8815243
    Abstract: The present invention relates to a pharmaceutical composition for promoting angiogenesis, containing an antibody that specifically binds to heat shock protein (HSP) 27. In addition, the present invention relates to a pharmaceutical composition containing an antibody that specifically binds to HSP 27, for treating an angiogenesis-dependent ailment selected from a group consisting of a wound, chronic ulcer, ischemic stroke, myocardial infarction, angina pectoris, and cerebrovascular dementia. In addition, the present invention relates to a method for promoting the in vitro growth of endothelial cells using an antibody that specifically binds to HSP27.
    Type: Grant
    Filed: August 18, 2011
    Date of Patent: August 26, 2014
    Assignee: Korea Institute of Radiological & Medical Sciences
    Inventors: Yoon Jin Lee, Yun-Sil Lee, Hae-June Lee, Seo-Hyun Choi, Kyeng-Jung Kim
  • In situ forming hydrogel and biomedical use thereof
    Patent number: 8815277
    Abstract: Disclosed are in situ-forming injectable hydrogel and medical uses thereof. In the in situ-forming injectable hydrogel two or more homogeneous or heterogeneous polymers are bonded to each other by a dehydrogenation reaction between phenol or aniline moieties on adjacent polymers, wherein a polymer backbone is grafted with a phenol or aniline moiety using a linker. In contrast to conventional hydrogel, the in situ-forming injectable hydrogel is superior in terms of in vivo stability and mechanical strength thanks to the introduction of a water-soluble polymer as a linker which leads to an improvement in the reactivity of phenol or aniline moieties. Having the advantage of superior bio stability and mechanical strength, the hydrogel finds a variety of applications in the biomedical field.
    Type: Grant
    Filed: July 1, 2010
    Date of Patent: August 26, 2014
    Assignee: Ajou University Industry-Academic Cooperation Foundation
    Inventors: Ki-Dong Park, Yoon-Ki Joung, Kyung-Min Park
  • MONOCLONAL ANTIBODY AGAINST HUMAN NON-SMALL CELL LUNG CARCINOMA AND USE THEREOF
    Publication number: 20140234327
    Abstract: The invention discloses a monoclonal antibody against human non-small cell lung carcinoma and a use of the monoclonal antibody. The monoclonal antibody is secreted by a hybridoma cell strain which is deposited as CCTCC Access Number No.: C201172. It has high yield and high titer, and has specific reactivity against lung adenocarcinoma and squamous carcinoma cell lines. Therefore, the monoclonal antibody may be applied in preparing drugs for treating human non-small cell lung carcinoma.
    Type: Application
    Filed: January 12, 2012
    Publication date: August 21, 2014
    Inventors: Shiyan Pan, Peijun Huang, Fang Wang
  • Semaphorin 3C (Sema3C) inhibitor therapeutics, methods, and uses
    Patent number: 8808693
    Abstract: Provided are methods, uses and pharmaceutical compositions for treatment of prostate cancer with a SEMA3C inhibitor in a biologically effective amount sufficient to cause cell death of a prostate cancer cell or to inhibit proliferation of the prostate cancer cells. The prostate cancer may be an androgen receptor (AR) positive prostate cancer and the SEMA3C inhibitor may be selected from one or more of the following: an antibody, a SEMA3C peptide, an antisense RNA, a siRNA, a shRNA or a small molecule.
    Type: Grant
    Filed: April 1, 2010
    Date of Patent: August 19, 2014
    Assignee: The University of British Columbia
    Inventors: Christopher J. Ong, Martin E. Gleave, Norihiro Hayashi, James Peacock
  • Methods of inhibiting the interaction of C5aR with C5a with anti-C5aR antibodies
    Patent number: 8808701
    Abstract: The present invention is directed to humanized antibodies which bind the human C5a receptor and their use as therapeutic and diagnostic agents. The present invention is further directed toward nucleic acid sequences which encode said humanized antibodies, and their expression in recombinant host cells. In particular, the present invention is directed towards humanized antibodies derived from murine antibody 7F3 which specifically binds to the human C5a receptor.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: August 19, 2014
    Assignee: G2 Inflammation Pty Ltd
    Inventors: Peter Whitfeld, David Zahra, Charles Reay Mackay
  • Optimized Fc variants and methods for their generation
    Patent number: 8809503
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: August 19, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Use of TNF alpha inhibitor for treatment of erosive polyarthritis
    Patent number: 8808700
    Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: August 19, 2014
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Rebecca S. Hoffman, Mark Weinberg
  • Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses
    Patent number: 8808667
    Abstract: The present invention relates to the use of a milled homogenate and/or a suspension and/or a cell lysate, stemming from a tumor resistant to at least one anti-tumoral compound in order to immunize and generate in vitro an antibody, or one of its functional fragments, directed against a tumoral antigen specifically expressed at the surface of said resistant tumor and being possibly involved in the resistance of said resistant tumor. More particularly, the present invention is directed to such antibodies obtained by applying the method, such as the antibodies 1A6, 1A9, 2E11, 3C11 and 3G7, as well as to their use for treating cancer.
    Type: Grant
    Filed: July 9, 2012
    Date of Patent: August 19, 2014
    Assignee: Pierre Fabre Medicament
    Inventors: Liliane Goetsch, Alexandra Jouhanneaud
  • AMINOPYRIMIDINE INHIBITORS OF TYROSINE KINASE
    Publication number: 20140227260
    Abstract: The present invention relates to new aminopyrimidine inhibitors of tyrosine kinase activity, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: April 21, 2014
    Publication date: August 14, 2014
    Applicant: Auspex Pharmaceuticals, Inc.
    Inventor: Chengzhi Zhang
  • THERAPEUTIC AGENT FOR PANCREATIC CANCER AND/OR BILIARY TRACT CANCER
    Publication number: 20140227282
    Abstract: The problem of the present invention is to provide a highly effective therapeutic drug for pancreatic cancer and/or biliary tract cancer. A therapeutic drug for pancreatic cancer and/or biliary tract cancer containing the following (1) and (2) as essential components: (1) at least one kind of branched-chain amino acid selected from the group consisting of isoleucine, leucine and valine, (2) gemcitabine or a salt thereof.
    Type: Application
    Filed: April 17, 2014
    Publication date: August 14, 2014
    Applicants: AJINOMOTO CO., INC., NATIONAL UNIVERSITY CORPORATION KOCHI UNIVERSITY
    Inventors: Shinobu NISHITANI, Kazuhiro HANAZAKI, Toshiji SAIBARA
  • Injectable, non-aqueous suspension with high concentration of therapeutic agent
    Patent number: 8802095
    Abstract: An injectable, nonaqueous suspension including at least one therapeutic agent suspended in a single component vehicle. The single component vehicle is a single amphiphilic material, such as a polyethoxylated castor oil or derivative thereof, a polyoxyethylene alkyl ether, a polyoxyethylene sorbitan fatty acid ester, a polyoxyethylene stearate, a block copolymer of polyethylene oxide-polypropylene oxide-polyethylene oxide, a block copolymer of polypropylene oxide-polyethylene oxide-polypropylene oxide, a tetra-functional block copolymer of polyethylene oxide-polypropylene oxide, or a tetra-functional block copolymer of polypropylene oxide-polyethylene oxide. A dosage kit that includes the injectable, nonaqueous suspension and a method of administering the injectable, nonaqueous suspension are also disclosed.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: August 12, 2014
    Assignee: Durect Corporation
    Inventors: Paul R. Houston, Guohua Chen, Andrew Sheung-King Luk
  • Formulation of human antibodies for treating TNF-? associated disorders
    Patent number: 8802102
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: January 3, 2014
    Date of Patent: August 12, 2014
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Compositions and methods for diagnosing and treating cancer
    Patent number: 8802103
    Abstract: Monoclonal antibodies that specifically bind to an extracellular domain of human Jagged 1 and inhibit growth of a tumor comprising cancer stem cells are described. Also described is a method of treating cancer that comprises administering a therapeutically effective amount of a monoclonal anti-Jagged 1 antibody.
    Type: Grant
    Filed: May 15, 2008
    Date of Patent: August 12, 2014
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin Gurney, Timothy Hoey, Sanjeev Satyal, Maureen Fitch Bruhns
  • Methods for treating retinopathy with extended therapeutic effect
    Patent number: 8802129
    Abstract: Methods for treating and preventing retinopathic conditions by administering a glucocorticoid to the vitreous chamber of a patient at risk of, or suffering from, the retinopathy.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: August 12, 2014
    Assignee: Allergan, Inc.
    Inventors: Scott M. Whitcup, David A. Weber
  • Use of transforming growth factor-beta neutralizing antibodies and fusion proteins thereof in treating pain
    Patent number: 8800906
    Abstract: Provided herein are methods for treating pain and for reducing the excitability of nociceptors, comprising administering a TGF-? antagonist. In some embodiments, a TGF-? antagonist is a monoclonal TGF-? neutralizing antibody or a fusion product comprising a monoclonal TGF-? neutralizing antibody, a soluble receptor, an antisense oligodeoxynucleotides (ODNs), a ribozymes, a small inhibitory RNA (siRNA), Smad 6, Smad7, or a small molecule that blocks TGF-? signaling.
    Type: Grant
    Filed: December 26, 2011
    Date of Patent: August 12, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventor: Pankaj J. Pasricha
  • Anti-RSPO1 antibodies
    Patent number: 8802097
    Abstract: The present invention relates to RSPO-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO proteins and modulate ?-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO proteins, such as antibodies that specifically bind RSPO1, RSPO2, and/or RSPO3 and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: August 12, 2014
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Fumiko Takada Axelrod, Timothy Charles Hoey, Cecile Chartier-Courtaud
  • Formulation of human antibodies for treating TNF-? associated disorders
    Patent number: 8802101
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: August 12, 2014
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Formulation of human antibodies for treating TNF-alpha associated disorders
    Patent number: 8802100
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: August 12, 2014
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • BMP-6 antibodies
    Patent number: 8795665
    Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, that bind to human BMP-6, compositions comprising such antibodies, or antigen-binding fragments thereof, and methods of using the same for treatment of anemia of chronic disease.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: August 5, 2014
    Assignee: Eli Lilly and Company
    Inventors: Neungseon Seo, Stephanie Marie Eaton Truhlar
  • Neuropilin antagonists
    Patent number: 8795660
    Abstract: Novel anti-NRP1 antibodies and variants thereof having unique structural and functional characteristics are disclosed. Also provided are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: August 5, 2014
    Assignee: Genentech, Inc.
    Inventors: Ryan J. Watts, Yan Wu